Switch from actin α1 to α2 expression and upregulation of biomarkers for pressure overload and cardiac hypertrophy in taurine-deficient mouse heart

Biological Chemistry

Volumn 387, Issue 10-11, 2006, Pages 1449-1454

  Warskulat, Ulrich ^a   Andrée, Birgit ^a   Lüsebrink, Jessica ^a   Köhrer, Karl ^a   Häussinger, Dieter ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Compatible organic osmolytes; Gene disruption; Knockout mice; Microarray

Indexed keywords

ALPHA ACTIN; ANKYRIN; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; DNA; MESSENGER RNA; OLIGONUCLEOTIDE; PROCOLLAGEN; TAURINE; ACTIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE MARKER; DNA HYBRIDIZATION; DNA MICROARRAY; FEMALE; GENE EXPRESSION; HEART FAILURE; HEART FUNCTION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; HYPERTENSION; KNOCKOUT MOUSE; MALE; MICROARRAY ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SPECIES COMPARISON; TAURINE DEFICIENCY; UPREGULATION; WESTERN BLOTTING; ANIMAL; ARTICLE; BLOOD PRESSURE; C57BL MOUSE; CARDIOMEGALY; GENETICS; HEART MUSCLE; ISOMERISM; METABOLISM; MOUSE; MOUSE MUTANT; PATHOPHYSIOLOGY;

ACTINS; ANIMALS; BIOLOGICAL MARKERS; BLOOD PRESSURE; CARDIOMEGALY; ISOMERISM; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIUM; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA, MESSENGER; TAURINE; UP-REGULATION;

EID: 33750611779     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/BC.2006.181     Document Type: Conference Paper

References (44)

1. Aihara, Y., Kurabayashi, M., Saito, Y., Ohyama, Y., Tanaka, T., Takeda, S., Tomaru, K., Sekiguchi, K., Arai, M., Nakamura, T., and Nagai, R. (2000). Cardiac ankyrin repeat protein is a novel marker of cardiac hypertrophy: role of M-CAT element within the promoter. Hypertension 36, 48-53.
2. Bishop, J.E., Rhodes, S., Laurent, G.J., Low, R.B., and Stirewalt, W.S. (1994). Increased collagen synthesis and decreased collagen degradation in right ventricular hypertrophy induced by pressure overload. Cardiovasc. Res. 28, 1581-1585.
3. Carrier, L., Boheler, K.R., Chassagne, C., de I Bastie, D., Wisnewsky, C., Lakatta, E.G., and Schwartz, K. (1992). Expression of the sarcomeric actin isogenes in the rat heart with development and senescence. Circ. Res. 70, 999-1005.
4. Chapman, R.A., Suleiman, M.S., and Earm, Y.E. (1993). Taurine and the heart. Cardiovascular Res. 27, 358-363.
5. Chen, Y.F. (2005). Atrial natriuretic peptide in hypoxia. Peptides 26, 1068-1077.
6. Clarkson, E., Costa, C.F., and Machesky, L.M. (2004). Congenital myopathies: diseases of the actin cytoskeleton. J. Pathol. 204, 407-417.
7. Clerico, A., Iervasi, G., Del Chicca, M.G., Emdin, M., Maffei, S., Nannipieri, M., Sabatino, L., Forini, F., Manfredi, C., and Donato, L. (1998). Circulating levels of cardiac natriuretic peptides (ANP and BNP). measured by highly sensitive and specific immunoradiometric assays in normal and in patients with different degrees of heart failure. J. Endocrinol. Invest. 21, 170-179.
8. Costa, C.F., Rommelaere, H., Waterschoot, D., Sethi, K.K., Nowak, K.J., Laing, N.G., Ampe, C., and Machesky, L.M. (2004). Myopathy mutations in α-skeletal-muscle actin cause a range of molecular defects. J. Cell Sci. 117, 3367-3377.
9. Crawford, K., Flick, R., Close, L., Shelly, D., Paul, R., Bove, K., Kumar, A., and Lassard, J. (2002). Mice lacking skeletal muscle actin show reduced muscle strength and growth deficits and die during the neonatal period. Mol. Cell. Biol. 22, 5887-5896.
10. 2+ changes in rat aortic smooth muscle cells. The role of atrial natriuretic peptide. Mol. Cell. Biochem. 252, 353-362.
11. Green, T.R., Fellman, J.H., Eicher, A.L., and Pratt, K.L. (1991). Antioxidant role and subcellular localization of hypotaurine and taurine in human neutrophils. Biochim. Biophys. Acta 1073, 91-97.
12. Heller-Stilb, B., van Royen, C., Rascher, K., Hartwig, H.G., Huth, A., Seeliger, M.W., Warskulat, U., and Häussinger, D. (2002). Disruption of the taurine transporter gene (taut) leads to retinal degeneration in mice. FASEB J. 16, 231-233.
13. Hewett, T.E., Grupp, I.L., Grupp, G., and Robbins, J. (1994). α-Skeletal actin is associated with increased contractility in the mouse heart. Circ. Res. 74, 740-746.
14. Huxtable, R.J. (1992). Physiological actions of taurine. Physiol. Rev. 72, 101-163.
15. Kostin, S., Hein, S., Arnon, E., Scholz, D., and Schaper, J. (2000). The cytoskeleton and related proteins in the failing heart. Heart Fail. Rev. 5, 271-280.
16. Kumar, A., Crawford, K., Close, L., Madison, M., Lorenz, J., Doetschmann, T., Pawlowski, S., Duffy, J., Neumann, J., Robbins, J., et al. (1997). Rescue of cardiac α-actin-deficient mice by enteric smooth muscle γ-actin. Proc. Natl. Acad. Sci. USA 94, 4406-4411.
17. Kurz, A.K., Schliess, F., and Häussinger, D. (1998). Osmotic regulation of the heat shock response in primary hepatocytes. Hepatology 28, 774-781.
18. Lake, N. (1993). Loss of cardiac myofibrils: mechanism of contractile deficits induced by taurine deficiency. Am. J. Physiol. 264, H1323-H1326.
19. Lloyd, C., Schevzov, G., and Gunning, P. (1992). Transfection of nonmuscle β- and γ-actin genes into myoblasts elicits different feedback regulatory responses from endogenous actin genes. J. Cell Biol. 117, 787-797.
20. Lofton, C.E., Baron, D.A., Heffner, J.E., Currie; M.G., and Newman, W.H. (1991). Atrial natriuretic peptide inhibits oxidant-induced increases in endothelial permeability. J. Mol. Cell. Cardiol. 23, 919-927.
21. Lopez, B., Gonzalez, A., Varo, N., Laviades, C., Querejeta, R., and Diez, J. (2001). Biochemical assessment of myocardial fibrosis in hypertensive heart disease. Hypertension 38, 1222-1226.
22. McHugh, K.M., Crawford, K., and Lessard, J.L. (1991). A comprehensive analysis of the developmental and tissue-specific expression of the isoactin multigene family in the rat. Dev. Biol. 148, 442-458.
23. Moise, N.S., Pacioretty, L.M., Kallfelz, F.A., Stipanuk, M.H., King, J.M., and Gilmour, R.F. Jr. (1991). Dietary taurine deficiency dilated cardiomyopathy in the fox. Am. Heart J. 121, 541-547.
24. Novotny, M.J., Hogan, P.M., Paley, D.M., and Adams, H.R. (1991). Systolic and diastolic dysfunction of the left ventricle induced by dietary taurine deficiency in cats. Am. J. Physiol. 261, H121-H127.
25. Pion, P.D., Kittleson, M.D., Rogers, Q.R., and Morris, J.G. (1987). Myocardial failure in cats associated with low plasma taurine: a reversible cardiomyopathy. Science 237, 764-768.
26. Pion, P.D., Kittleson, M.D., Thomas, W.P., Skiles, M.L., and Rogers, Q.R. (1992). Clinical findings in cats with dilated cardiomyopathy and relationship of findings to taurine deficiency. J. Am. Vet. Med. Assoc. 201, 167-274.
27. Rubattu, S. and Volpe, M. (2001). The atrial natriuretic peptide: a changing view. J. Hypertens. 19, 1923-1931.
28. Ruzicka, D.L. and Schwartz, R.J. (1988). Sequential activation of alpha-actin genes during avian cardiogenesis: vascular smooth muscle α-actin gene transcripts mark the onset of cardiomyocyte differentiation. J. Cell Biol. 107, 2575-2586.
29. 2+ channels. Cell Calcium 11, 251-259.
30. Schaffer, S.W. and Azuma, J. (1992). Myocardial physiological effects of taurine and their significance. In: Taurine, J.B. Lombardini, ed. (New York, USA: Plenum Press), pp. 105-120.
31. Schaub, M.C., Hefti, M.A., Harder, B.A., and Eppenberger, H.M. (1997). Various hypertrophic stimuli induce distinct phenotypes in cardiomyocytes. J. Mol. Med. 75, 901-920.
32. Schwartz, K., de la Bastie, D., Bouveret, P., Oliviero, P., Alonso, S., and Buckingham, M. (1986). α-Skeletal muscle actin mRNAs accumulate in hypertrophied adult rat hearts. Circ. Res. 59, 551-555.
33. Schwartz, K., Carrier, L., Chassagne, C., Wisnewsky, C., and Boheler, K.R. (1992). Regulation of myosin heavy chain and actin isogenes during cardiac growth and hypertrophy. Symp. Soc. Exp. Biol. 46, 265-272.
34. Sun, Y. and Weber, K.T. (1996). Angiotensin converting enzyme and myofibroblasts during tissue repair in the rat heart. J. Mol. Cell. Cardiol. 28, 851-858.
35. Timbrell, J.A., Saebra, V., and Waterfield, C.J. (1995). The in vivo and in vitro protective properties of taurine. Gen. Pharmacol. 26, 453-462.
36. Van Bilsen, M. and Chien, K.R. (1993). Growth and hypertrophy of the heart: towards an understanding of cardiac specific and inducible gene expression. Cardiovasc. Res. 27, 1140-1149.
37. Vandekerckhove, J. and Weber, K. (1978). At least six different actins are expressed in a higher mammal: an analysis based on the amino acid sequence of the amino-terminal tryptic peptide. J. Mol. Biol. 126, 783-802.
38. Vandekerckhove, J., Bugaisky, G., and Buckingham., M. (1986). Simultaneous expression of skeletal muscle and heart actin proteins in various striated muscle tissues and cells. J. Biol. Chem. 261, 1838-1843.
39. Warskulat, U., Flögel, U., Jacoby, C., Hartwig, H.G., Thewissen, M., Merx, M.W., Molojavyi, A., Heller-Stilb, B., Schrader, J., and Häussinger, D. (2004). Taurine transporter knockout depletes muscle taurine levels and results in severe skeletal muscle impairment but leaves cardiac function uncompromised. FASEB J. 18, 577-579.
40. Welch, W.J. and Brown, R. (1996). Influence of molecular and chemical chaperones on protein folding. Cell Stress Chaperones 1, 109-115.
41. Wettstein, M. and Häussinger, D. (1997). Cytoprotection by the osmolytes betaine and taurine in ischemia-reoxygenation injury in the perfused rat liver. Hepatology 26, 1560-1566.
42. Winegrad, S., Wisnewsky, C., and Schwartz, K. (1990). Effect of thyroid hormone on the accumulation of mRNA for skeletal and cardiac α-actin in hearts from normal and hypophysectomized rats. Proc. Natl. Acad. Sci. USA 87, 2456-2460.
43. Woodcock-Mitchell, J., Mitchell, J.J., Low, R.B., Kieny, M., Sengel, P., Rubbia, L., Skalli, O., Jackson, B., and Gabbiani, G. (1988). α-Smooth muscle actin is transiently expressed in embryonic rat cardiac and skeletal muscle. Differentiation 39, 161-166.
44. Woods, R.L. (2004). Cardioprotective functions of atrial natriuretic peptide and B-type natriuretic peptide: a brief review. Clin. Exp. Pharmacol. Physiol. 31, 791-794.